A Multi-center, Open-label, Randomized Trial in India to Investigate the Efficacy and Safety of a Single Injection of MK-8962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation Using Daily Recombinant FSH as a Reference (Phase III, Protocol No. MK-8962-029-00 [Also Known as SCH900962, P07056])

Trial Profile

A Multi-center, Open-label, Randomized Trial in India to Investigate the Efficacy and Safety of a Single Injection of MK-8962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation Using Daily Recombinant FSH as a Reference (Phase III, Protocol No. MK-8962-029-00 [Also Known as SCH900962, P07056])

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2013

At a glance

  • Drugs Corifollitropin alfa (Primary) ; Chorionic gonadotropin; Follitropin beta; Ganirelix; Progesterone
  • Indications Female infertility
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 21 Oct 2013 Planned End Date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 21 Oct 2013 Planned initiation date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top